Recently, a study has demonstrated that UBE2C upregulation was relevant to the advanced histologic grade, FIGO stage, and recurrence and might be a new biomarker for the diagnosis and therapy of endometrial cancer [33]. This evidence concerns the gene UBE2C and endometrial cancer.